Skip to content
stoqly

Acadia Healthcare

ACHC Nasdaq Health Care Facilities Financials FY2016–FY2025

Acadia Healthcare's revenue rose 5.0% to $3.3 billion in fiscal 2025. Its net margin was −33.3%, down from 8.1% a year earlier. Free cash flow was −$440 million. It paid out $50 million in dividends and buybacks. The diluted share count fell 1.5%.

Last close · Oct 23, 2026

$31.51

1.2%
Value it Compare
Revenue Total sales reported in the income statement.
$3.3B
5.0% vs prior year
Operating margin Operating income as a share of revenue.
—
Net income Profit after all expenses, interest and tax.
−$1.1B
531.5%
Free cash flow Cash from operations minus capital spending.
−$440M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−16.0%
23.8 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$2.9B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—

About these figures. Acadia Healthcare's 2025 loss of about US$1.1 billion leaves its earnings before interest, tax, depreciation and amortization negative, so net debt to EBITDA is blank for that year.

What Acadia Healthcare does

No business description yet.

Legal name
Acadia Healthcare Company, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001193125-26-078266
0001520697

Revenue and margins

Acadia Healthcare had $3.3B of revenue in fiscal 2025, up 5.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$440M in fiscal 2025, −13.3% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Acadia Healthcare returned $50.0M to shareholders in fiscal 2025. The diluted share count fell 1.5%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Acadia Healthcare yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.4B and divides by 90.7M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Balance sheet

Cash, debt and the ratios that show how comfortably Acadia Healthcare can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $134M$97.6M$100M$76.3M$133M
Debt incl. finance leases $1.5B$1.4B$1.4B$2.0B$2.5B
Net debt / EBITDA 2.9x2.3x6.8x3.1x—
Debt / equity 0.6x0.5x0.5x0.6x1.3x
Interest coverage 3.9x6.7x0.7x4.0x−7.6x
Current ratio 1.2x1.3x0.7x1.0x1.6x
Quick ratio 1.2x1.3x0.7x1.0x1.5x
Total assets $4.8B$5.0B$5.4B$6.0B$5.5B
Total liabilities $2.2B$2.1B$2.5B$2.8B$3.4B
Shareholders' equity $2.5B$2.8B$2.8B$3.1B$1.9B
Net debt (− = net cash) $1.4B$1.3B$1.3B$1.9B$2.4B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✓ ✕
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✓ ✕
Cash from operations exceeds net income ✓ ✕ ✓
Debt fell relative to assets ✓ ✕ ✕
Current ratio rose ✕ ✓ ✓
Share count didn't rise ✓ ✕ ✓
Gross margin rose — — —
Revenue rose relative to assets ✓ ✓ ✕
F-score 5 / 85 / 84 / 8
Accruals ratio −9.4%2.2%−21.5%
Altman Z'' 0.981.89−0.65

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Acadia Healthcare ACHC $2.9B 5.0% — −13.3% −16.0% — 4
Astrana Health ASTH $1.9B 56.4% 2.5% 3.3% 4.2% 45.1x 4 Compare →
Ensign Group ENSG $10.4B 18.7% 8.4% — 19.7% 27.5x 6 Compare →
Option Care Health OPCH $4.9B 13.0% 6.0% 3.8% 11.4% 24.4x 5 Compare →
Encompass Health EHC $12.4B 10.5% — 7.4% 15.8% 20.2x 8 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $2.8B $2.8B $1.9B $2.0B $2.1B $2.3B $2.6B $2.9B $3.2B $3.3B
Operating income $609M $604M $594M $586M — — — — — —
Interest expense $161M $159M $175M $173M $138M $93.7M $65.7M $80.7M $113M $125M
Pretax income $33.0M $237M $67.4M $78.4M $184M $276M $374M −$25.4M $342M −$1.1B
Income tax $28.8M $37.2M $9.9M $25.1M $40.6M $67.6M $94.1M −$9.7M $77.4M $26.0M
Net income $6.1M $200M −$176M $109M −$672M $191M $273M −$21.7M $256M −$1.1B
Diluted EPS $0.07 $2.30 −$2.01 $1.24 −$7.59 $2.10 $2.98 −$0.24 $2.78 −$12.16
Diluted shares 0.09B 0.09B 0.09B 0.09B 0.09B 0.09B 0.09B 0.09B 0.09B 0.09B
Cash flow
Cash from operations $362M $400M $414M $333M $659M $375M $381M $462M $130M $132M
Capital expenditure $308M $274M $253M $233M $225M $245M $296M $424M $690M $572M
Free cash flow $54.0M $125M $161M $100M $434M $130M $84.4M $38.2M −$561M −$440M
Depreciation and amortization $135M $143M $80.3M $87.9M $95.3M $107M $118M $132M $150M $189M
Stock-based compensation $28.3M $23.5M $22.0M $17.3M $22.5M $37.5M $29.6M $32.3M $37.1M $31.7M
Acquisitions $684M $18.2M $0.0M $44.9M $0.0M $139M $9.5M $0.3M $53.5M $8.2M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $50.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $50.0M
Balance sheet
Cash and short-term investments $57.1M $67.3M $50.5M $99.5M $379M $134M $97.6M $100M $76.3M $133M
Total debt $3.3B $3.2B $3.2B $3.1B $3.1B $1.5B $1.4B $1.4B $2.0B $2.5B
Finance lease liabilities $0.0M $0.0M $0.0M $50.5M $42.9M $11.8M $11.8M $11.9M $11.9M $11.8M
Current assets $428M $472M $450M $542M $2.5B $495M $506M $596M $578M $814M
Current liabilities $343M $377M $416M $464M $1.3B $405M $388M $886M $578M $525M
Inventory $4.6M $4.8M $5.1M $4.1M $4.9M $4.8M $5.1M $5.3M $5.7M $5.7M
Property and equipment, net $2.7B $3.0B $3.1B $1.5B $1.6B $1.8B $2.0B $2.3B $2.9B $3.1B
Total assets $6.0B $6.4B $6.2B $6.9B $6.5B $4.8B $5.0B $5.4B $6.0B $5.5B
Total liabilities $3.8B $3.8B $3.8B $4.3B $4.5B $2.2B $2.1B $2.5B $2.8B $3.4B
Shareholders' equity $2.2B $2.6B $2.3B $2.5B $1.9B $2.5B $2.8B $2.8B $3.1B $1.9B
Margins
Operating margin 21.7% 21.3% 31.2% 29.2% — — — — — —
EBITDA margin 26.5% 26.4% 35.4% 33.6% 19.9% 20.6% 21.4% 6.4% 19.2% −22.7%
Net margin 0.2% 7.1% −9.2% 5.4% −32.2% 8.2% 10.5% −0.7% 8.1% −33.3%
FCF margin 1.9% 4.4% 8.5% 5.0% 20.8% 5.6% 3.2% 1.3% −17.8% −13.3%
Returns
Return on capital 6.5% 9.1% 9.0% 7.2% 4.9% 6.5% 8.2% 1.1% 7.8% −16.0%
Return on capital employed 12.6% 10.3% 10.1% 9.6% 5.5% 7.7% 9.8% 1.2% 9.2% −18.1%
Return on equity 0.3% 8.4% −7.2% 4.5% −30.5% 8.6% 10.3% −0.8% 8.7% −43.9%
Return on assets 0.1% 3.2% −2.8% 1.7% −10.1% 3.4% 5.6% −0.4% 4.5% −19.2%
Growth
Revenue growth — 0.9% −32.9% 5.4% 4.1% 10.7% 12.8% 12.2% 7.7% 5.0%
Net income growth −94.5% 3,153.1% −188.0% — −717.1% — 43.3% −107.9% — −531.4%
EPS growth −95.7% 3,185.7% −187.4% — −712.1% — 41.9% −108.1% — −537.4%
FCF growth — 132.2% 28.3% −37.7% 332.9% −70.1% −34.9% −54.7% −1,567.5% —
Share count change 25.7% 1.3% 0.4% 0.5% 0.9% 2.5% 0.8% −0.7% 1.2% −1.5%
Financial health
Net debt / EBITDA 4.3x 4.3x 4.7x 4.6x 6.7x 2.9x 2.3x 6.8x 3.1x —
Debt / equity 1.5x 1.3x 1.4x 1.3x 1.7x 0.6x 0.5x 0.5x 0.6x 1.3x
Interest coverage 3.8x 3.8x 3.4x 3.4x 2.3x 3.9x 6.7x 0.7x 4.0x −7.6x
Current ratio 1.3x 1.3x 1.1x 1.2x 1.9x 1.2x 1.3x 0.7x 1.0x 1.6x
Quick ratio 1.2x 1.2x 1.1x 1.2x 1.9x 1.2x 1.3x 0.7x 1.0x 1.5x
Capital allocation
Capex / revenue 10.9% 9.7% 13.3% 11.6% 10.8% 10.6% 11.3% 14.5% 21.9% 17.3%
Stock comp / revenue 1.0% 0.8% 1.2% 0.9% 1.1% 1.6% 1.1% 1.1% 1.2% 1.0%
Payouts / FCF 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% — —
Quality scores
Piotroski F-score — 6.0 3.0 7.0 4.0 6.0 6.0 5.0 5.0 4.0
Altman Z'' 1.5 1.7 1.5 1.4 1.8 1.8 2.3 1.0 1.9 −0.7
Accruals ratio −6.9% −3.2% −9.4% −3.4% −19.9% −3.3% −2.2% −9.4% 2.2% −21.5%

Source: SEC EDGAR XBRL filings (CIK 0001520697). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open